Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29190477 | 0.84 | TMEM97 (0.41) | TMEM97SIGMAR1ADRA2A | |
| SCHEMBL11401469 | 0.84 | TMEM97 (0.47) | TMEM97SIGMAR1ADRA2AOPRM1 | |
| SCHEMBL11401467 | 0.84 | TMEM97 (0.47) | TMEM97SIGMAR1ADRA2AOPRM1 | |
| Hydrochloric Acid SCHEMBL11321319 | 0.83 | TMEM97 (0.46) | TMEM97SIGMAR1ADRA2AOPRM1 | |
| SCHEMBL3406036 | 0.81 | SIGMAR1 (0.37) | TMEM97SIGMAR1ADRA2AOPRM1OPRD1 | |
| SCHEMBL736557 | 0.81 | SIGMAR1 (0.52) | SIGMAR1ADRA2AOPRM1OPRD1 | |
| SCHEMBL2360287 | 0.81 | SIGMAR1 (0.52) | SIGMAR1ADRA2AOPRM1OPRD1 | |
| SCHEMBL24203981 | 0.80 | MEN1 (0.37) | SIGMAR1ADRA2AOPRM1OPRD1OPRK1 | |
| SCHEMBL11864088 | 0.80 | SIGMAR1 (0.54) | SIGMAR1ADRA2AOPRM1OPRD1OPRK1 | |
| SCHEMBL30376318 | 0.80 | MEN1 (0.37) | SIGMAR1ADRA2AOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960402-B2 | Trans-5'-(2-fluoroethoxy)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-isobenzofuran]-4-carboxamide hydrochloride; histamine H3 receptor antagonist or inverse agonist; metabolic disorders; circulatory diseases; nervous system diseases; psychological disorders; sleep disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-1795527-B1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | MSD K.K. (JP) | 2008-07-17 | — | — | US | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | HRH3, HRH4, HRH2 | TMEM97 997/4885SIGMAR1 121/4885ADRA2A 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.